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a b s t r a c t
Different reports suggest that nociceptin/orphanin FQ (N/OFQ) may have either anxiolytic-
or anxiogenic-like effect in rodents. Since N/OFQ elicits hypolocomotion, which undergoes
rapid tolerance, and hypolocomotion may be associated to emotional consequences, the
present study was designed to investigate the effect of N/OFQ on anxiety after development
of tolerance to its hypolocomotor effect. The effect of single or double intracerebroven-
tricular (i.c.v.) injection of N/OFQ was evaluated on anxiety-related behaviors in rats, in the
elevated plus maze (EPM) and conditioned defensive burying (CDB) tests. After single
administration, N/OFQ displayed an anxiogenic-like pattern of response on the elevated
plus maze but hypolocomotion was also observed. Conversely, in the CDB test, N/OFQ
induced a clear-cut anxiolytic pattern. To produce tolerance to N/OFQ-induced hypoloco-
motion the peptide was administered by two i.c.v. injections separated by 120 min; in these
conditions it decreased the expression of anxiety-related behaviors in both tests without
affecting locomotor activity. The nociceptin/orphanin FQ peptide (NOP) receptor antagonist
UFP-101 significantly reduced the effects of N/OFQ to control values in either tests. Corti-
costerone levels were significantly increased after a single N/OFQ administration (not in a
dose-dependent manner) but this increase did not reach significance after double admin-
istration (1 nmol/rat). Our results support the idea that N/OFQ may act as an anxiolytic-like
agent in the rat; the apparent anxiogenic-like effect observed following its single admin-
istration in the EPM may be consequent to its effect on locomotion.
# 2006 Elsevier Inc. All rights reserved.
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First identified in 1995, the 17-amino acid peptide nociceptin/
orphanin FQ (N/OFQ) is the endogeous ligand for the ‘‘orphan’’
opioid receptor ORL-1 (now NOP) [32,45]. N/OFQ is quite
selective for NOP receptor, while showing no appreciable
affinity for m opioid (MOP), d opioid (DOP) or k opioid (KOP)
receptors [34,51,53,24,31]. Nevertheless, studies on the cellular* Corresponding author. Tel.: +39 059 2055370; fax: +39 059 2055376.
E-mail address: vitale.giovanni@unimore.it (G. Vitale).
0196-9781/$ – see front matter # 2006 Elsevier Inc. All rights reserved
doi:10.1016/j.peptides.2006.04.003effects and the underlying transduction mechanisms pointed
out important commonalities between N/OFQ and classic
opioid agonists. Like opioid agonists, N/OFQ inhibits adenylate
cyclase and calcium currents and hyperpolarizes neurons by
opening potassium channels [20,35].
N/OFQ administration inhibits locomotor activity after
intracerebroventricular (i.c.v.) injection of doses of 1–10 nmol
[45,9], while it has been reported to increase locomotion at.
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responses to nociceptive stimuli, stimulates feeding behavior,
blocks morphine place conditioning and the reinforcing
effects of ethanol, interfers with learning and memory
functions and alters sensory processing as well [3,5,33].
N/OFQ and NOP receptors are abundantly expressed in
limbic and limbic-associated brain structures [16,15,39,40] that
are involved in processing of emotionally relevant stimuli,
thus raising the hypothesis that N/OFQ might contribute to
regulation of the hypothalamic–pituitary–adrenal (HPA) axis,
and to regulation of emotional states. Accordingly, i.c.v.
injection of N/OFQ or of the NOP receptor agonist Ro 64-
6198 were shown to decrease behavioral responses to stress
[18,21–23,50]. PreproN/OFQ knockout mice express high levels
of anxiety-related behavior in neophobic tests, suggesting that
an intact N/OFQ system is necessary for normal anxiety
responses [23]. Furthermore, acute stress exposure decreases
N/OFQ content in forebrain neurons, implicating endogenous
N/OFQ neurotransmission in physiological stress responses
[12]. However, N/OFQ was also reported to elicit anxiogenic-
like responses, to increase plasma concentrations of adreno-
corticotropic hormone (ACTH) and corticosterone (CORT) in
unstressed rats and to augment hormonal responses inmildly
stressed rats [11].
Thus, the literature on this subject is not unanimous: there
are reports suggesting an anxiolytic-like effect of N/OFQ
[21,18,22,52,7,17], but there are also reports suggesting an
anxiogenic-like effect for the peptide [13]. N/OFQ is well
known to elicit a clear-cut hypolocomotor effect in rats, which
undergoes rapid tolerance [9]. Since hypolocomotion may be
associated to emotional consequences, particularly in stress-
ful conditions, the present study was designed to investigate
the effect of N/OFQ both following acute and repeated
administration of the peptide with the aim of minimizing
its effect on locomotion.
Two different behavioral tests were used: the elevated plus
maze and the conditioned defensive burying in rats, which
measure fear-like responses of a composite nature, generated
by exposure to stressful environmental conditions. These
classic paradigms were established for their sensitivity to
conventional anxiolytic tranquilizers and anxiogenic com-
pounds of various structural classes and mechanisms of
action. In particular, the elevated plusmazemodel is based on
rats’ innate aversion to open and high places and belongs to
the group of unconditioned anxiety paradigms used for the
development of putative anxiolytic compounds [25,28]. On the
other hand, defensive burying is an innate response exhibited
by rats towards aversive stimuli. The defensive burying
behavior test has been extensively used to study the neuronal
mechanisms underlying anxiety regulation, and was chosen
for the present investigation on the basis of its sensitivity to
manifest both physiological and pharmacological changes in
anxiety [49]. The tests had been previously validated, in our
experimental conditions, with prototypical anxiolytic com-
pounds (i.e. diazepam) and had been controlled for effects on
sensorimotor function (data not shown). Serumcorticosterone
(CORT) levels were also evaluated in rats during exposure to
the anxiety test after either a single or a double N/OFQ
treatment. Moreover, the NOP receptor antagonist UFP-101
was tested in the double N/OFQ administration experimentswhere a rapid development of tolerance to hypolocomotion
can occur. Indeed, data obtained in ‘‘in vitro’’ and in ‘‘in vivo’’
tests have demonstrated that UFP-101 behaves as a potent,
competitive and selective antagonist at NOP receptors (for a
review, see Calo` et al. [4]).
The present study sought to shed new light on the
contrasting evidences regarding the N/OFQ effects on anxi-
ety-related behaviors; for this purpose we operated in
conditions devoid of locomotor impairment, we utilized
differential anxiety tests and also examined how the blockade
of N/OFQ-NOP signaling can affect this complex emotional
behavior.2. Materials and methods
2.1. Animals
Two hundred male Wistar rats weighing 180–200 g, at the
beginning of the experiments,werehoused in Plexiglas1 cages
in groups of three to four in controlled conditions (free access
to food and water; 12-h light:12-h dark cycle; temperature,
22  1 8C; humidity, 60%). All testing sessions were performed
between 09:00 and 14:00 h. Ethical guidelines for investigation
of experimental pain in conscious animals were followed, and
procedures were carried out according to EEC ethical regula-
tions for animal research (EEC Council 86/609; D.Lgs. 27/01/
1992, no. 116).
2.2. Surgery
The rats were randomly divided into groups of 10 animals
each. For i.c.v. injections, stainless-steel guide cannulae
(23 ga) (Plastic One, Roanoke, VA, USA) were stereotaxically
implanted in the right lateral ventricle, to a depth of 0.5 mm
above the ventricle (inmm from the bregma: AP = 0.8; L = 1.4;
V = 3.25) [41], under ketamine plus xylazine anesthesia
(115 + 2 mg/kg i.p.; Farmaceutici Gellini, Aprilia, Italy and
Bayer, Milan, Italy, respectively) and fixed in place with acrylic
dental cement and one skull screw. A removable plugwas kept
in place except during the drug injections. All i.c.v. injections
were in a volume of 5 ml. After the end of the experiment, rats
were i.c.v. injected with 5 ml of dye (Evans Blue) and sacrificed
under anesthesia. The correct placement of the cannula was
ascertained by inspection of dye diffusion in the right lateral
ventricle.
2.3. Experimental procedure
In the first set of experiments N/OFQ, 0.3, 0.5, 0.75, 1 and
1.5 nmol/rat, or saline was i.c.v. injected in a single admin-
istration by means of an injector (1 mm longer than the guide
cannula) and the animals (n = 10 per group) were subjected
either to the elevated plus maze test or to the conditioned
defensive burying test 5 min later (amount of rats in
experiment 1 = 120). The rats belonging to the groups
submitted to the plus maze test were decapitated 20 min
after the end of the test, their blood collected from the trunk,
centrifuged at 1000  g for 10 min and serum was removed
and stored at 808C until analysis for corticosterone content
p e p t i d e s 2 7 ( 2 0 0 6 ) 2 1 9 3 – 2 2 0 0 2195using enzyme immunoassay (see below). Taking into account
the circadian rhythmof corticosterone, all blood sampleswere
taken between 12.00 and 14.00, i.e. during the diurnal period
when its concentrations are relatively constant [1] in order to
minimize its fluctuations.
In the second set of experiments the animals were
pretreated with the dose of 1 nmol/rat of N/OFQ (or saline,
same volume) 2 h before the subsequent treatment which
consisted in the administration of UFP-101 (10 nmol/rat), or
saline, 5 min before N/OFQ (1 nmol/rat), or saline (amount of
rats in experiment 2 = 80). The animalswere then submitted to
the same experimental procedure as previously described.
2.4. Elevated plus maze test
The elevated plus maze consisted of two open arms and two
enclosed arms each measuring 55 cm  10 cm, with black
wooden floors, emanating from a common central platform
(10 cm  10 cm) to form a plus shape. The open arms were
bounded by 1 cm high ledges on the sides, but there were no
ledges at the ends of the arms. The closed armshad 40 cmhigh
transparent Plexiglas walls. The maze was elevated 80 cm
above the ground. The rats were brought to the room in a clear
plastic neutral box measuring 32 cm  22 cm  11 cm.
From the fifth day after surgery, each animal was treated
with saline or NOP agonist and/or antagonist and submitted to
the elevated plus maze test. The animal was placed in the
centre of the maze (central platform = arena) facing an open
arm and its behavior recorded by an expert group of
experimenters, unaware of the treatments, for a period of
5 min. At the end of each test, the animalwas removed and the
maze floor was thoroughly cleaned.
Several measures of anxiety-related parameters, as well as
motor activity, were obtained through the recording. For each
5 min block, the amount of time that the animal spent engaged
in locomotor activity in each portion of themazewas recorded.
Behavioral determinations in the elevated plus maze
included the number of open or closed arm entries (defined
as the movements of all four paws from one arm to another)
and the time spent in open, closed arms and in the central
platform [43].
2.5. Conditioned defensive burying test
A rectangular Plexiglas burying apparatus consisting of an
acryilic cage (27 cm wide  38 cm long and 38 cm high), with
the floor covered with fine sawdust, was used. A continuously
electrified probe consisting ofwireswrappedaroundawooden
dowel was positioned in the apparatus so that it protruded
10.3 cm into the chamber and was 7.5 cm from the bottom of
the chamber. Contact with the probe produced a shock of
1 mA. Bedding in the chamber was approximatively 5.0 cm in
depth. Animals were habituated (three to four cagemates
together) to the apparatus, in the absence of the shock probe,
for 15 min each day for 4 consecutive days.
On fifth day, rats were tested individually for 15 min with
the electrified probe in place. The height of bedding behind the
probe was measured before testing and at the end of each
30 min test period and was expressed as the height of bedding
above the 5.0 cm of bedding already placed in the chamber.Fresh beddingwas placed in the apparatus before testing each
animal. Behavior during the 30 min test period was recorded
and later scored by two independent observers unaware of the
treatments. Behaviors measured were: latency to first contact
with the probe and to be shocked, latency to initiate burying
(defined as pushing bedding material with the snout of
forelimbs forward in the direction of the prod) from first
contact, total number of shocks received, height of buried
bedding and duration of burying behavior over the entire test
period [44]. In particular, the latency intended as the time
elapsing from the first shock to the display of the burying
behavior inversely reflects the animal’s reactivity while the
cumulative time of burying behavior has been suggested to
reflect the rats’ anxiety levels in a specific manner [48,6].
2.6. Serum corticosterone assay
Assessment of serum corticosterone was done bymeans of an
enzyme immunoassay (EIA) using a commercially available kit
(Assay Design Inc., Ann Arbor, MI, USA) which utilizes a
microplate reader set at 405 nm. Serum samples were diluted
1:20 in the appropriate assay buffer in order to be within the
calibration curve range. The detection limit of the assay was
26.99 pg/ml; intraassay and interassay coefficients of varia-
tions were, respectively, 7.8 and 9.8%.
2.7. Drugs
The heptadecapeptide N/OFQ (Phe-Gly2-Phe-Thr-Gly-Ala-Arg-
Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) was purchased from
Bakem,Merseyside, UK; [Nphe1] Arg14, Lys15-N/OFQ-NH2 (UFP-
101) was kindly supplied by Drs. R. Guerrini and G. Calo`
(University of Ferrara).
2.8. Statistical analysis
All values are expressed as mean S.E.M. A one-way ANOVA
followed by Bonferroni test was used to analyze the effects of a
treatment with increasing doses of N/OFQ in the elevated plus
mazeor in the conditioned defensive burying tests aswell as on
corticosterone levels. A two-way ANOVA was used to analyze
the effects ofUFP-101pretreatment,N/OFQ treatment and their
interaction. The Bonferroni post hoc test was used for the two-
way ANOVA when the effects of UFP-101 and N/OFQ were
separately evaluated. The level of significance was set at 0.05.3. Results
3.1. Anxiety tests following single injection
In our first set of experiments, rats were treated with a single
i.c.v. administration of N/OFQ at doses ranging from 0.3 to
1.5 nmol/rat.
At the doses of 0.3 and 0.5 nmol/rat, N/OFQ induced no
changes in the elevated plus maze and all values were no
different from those of the control group. The higher doses
(0.75, 1 and 1.5 nmol/rat) induced a significant decrease in the
time spent in the open arms [ANOVA: F(5,54) = 33.26, P < 0.01]
together with an increase in the time spent in the closed arms
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Table 1 – Effect of the single administration with increasing doses of nociceptin/orphanin FQ (N/OFQ, 0.3–1.5 nmol/rat) in
the elevated plus maze test in the rat
Treatment Time spent
in the open
arms (s)
Time spent
in the closed
arms (s)
Time spent
in the central
platform (s)
Open arm
entry
counts
Closed arms
entry
counts
Motor activity
in the open
arms (s)
Motor activity
in the closed
arms (s)
Saline 85.4  10.6 171.8  9.9 42.7  4.3 3.23  0.45 6.01  0.63 24.12  3.13 46.28  5.10
N/OFQ, 0.3 nmol 78.8  9.7 181.2  10.7 40.1  4.2 3.13  0.56 5.63  0.61 22.17  497 39.78  5.97
N/OFQ, 0.5 nmol 75.0  7.9 184.2  11.1 41.1  4.7 3.21  0.65 4.89  0.52 24.53  6.41 43.26  4.88
N/OFQ, 0.75 nmol 8.9  4.6* 218.6  9.7* 72.5  6.9* 2.87  0.81 2.57  0.78* 4.91  2.01* 16.51  6.01*
N/OFQ, 1.0 nmol 4.9  1.8* 221.7  9.4* 73.4  6.8* 2.07  0.76 1.61  0.70* 3.12  1.97* 7.17  3.84*
N/OFQ, 1.5 nmol 0.9  1.0* 224.3  10.1* 75.1  7.0* 2.23  0.79 1.29  0.94* 0.48  0.40* 6.51  3.44*
N/OFQ or saline were i.c.v. administered 5 min before the elevated plus maze test. Values ere expressed as mean  S.E.M. for 10 rats for each
group.
* P < 0.05 vs. saline (one-way ANOVA followed by Bonferroni test).[F(5,54) = 5.63, P < 0.01] and in the central arena [F(5,54) = 9.36,
P < 0.01]. These effects appear to proceed in a dose-dependent
manner and may be interpreted as an anxiogenic-like pattern
of response. However, other changes were associated to the
previous ones: a significant decrease in locomotion in both
arms [F(5,54) = 9.47, P < 0.01 for open arms; F(5,54) = 13.94,
P < 0.01 for closed arms] and in the number of entries in the
closed arms [F(5,54) = 8.71, P < 0.01] (Table 1).
In the conditioned defensive burying test, neither the
latency to first shock nor the burying behavior latency was
modified by N/OFQ at any dose used (Table 2). Furthermore,
therewas no significant difference in the number of times rats
received shocks from contacting the probe. Conversely, N/OFQ
induced a reduction of the cumulative burying behavior
associated with a decrease in the height of buried bedding,
both of which were statistically significant [ANOVA:
F(5,54) = 11.13, P < 0.01 and F(5,54) = 17.24, P < 0.01, respec-
tively], beginning from the dose of 0.75 nmol/rat.
3.2. Anxiety tests following repeated injection
A second set of experiments was performed pretreating the
animals with the same dose of N/OFQ (1 nmol/rat) 2 h before
treatment. In the plus maze test, the double treatment
completely abolished the hypolocomotor effect induced by
the single injection of N/OFQ and induced a significant
increase in the number of the open arm entries [ANOVA:
F(3,36) = 11.89, P < 0.01] and in the time spent there
[F(3,36) = 8.45, P < 0.01], associated with a reduction in theTable 2 – Effect of the single administration with increasing do
the conditioned defensive burying test in the rat
Treatment Latency to first
shock (s)
Latency to bury followin
the shock (s)
Saline 28.8  3.5 173.4  18.8
N/OFQ, 0.3 nmol 34.6  5.1 218.4  20.3
N/OFQ, 0.5 nmol 38.4  6.2 249.2  21.6
N/OFQ, 0.75 nmol 30.9  3.8 231.2  20.5
N/OFQ, 1.0 nmol 24.6  7.2 261.4  20.9
N/OFQ, 1.5 nmol 33.7  5.7 217.2  19.9
N/OFQ or saline were i.c.v. administered 5 min before the defensive bur
group.
* P < 0.05 vs. saline (one-way ANOVA followed by Bonferroni test).time spent in the closed arms [F(3,36) = 4.95, P < 0.01]. An
increase in locomotor activity in the open arms was recorded
too [F(3,36) = 23.62, P < 0.01]. In this second experiment N/OFQ
did not show any reduced effect on total locomotor activity
and revealed an anxiolytic-like action regarding the above
mentioned parameters. The treatment with UFP-101, admi-
nistered alone at the dose of 10 nmol/rat, induced no
significant change in the behavioral parameters in this test
but it completely abolished the effect of N/OFQ (1 nmol/rat),
bringing back all the parameters to control values (Table 3).
In thedefensive burying test, the repeated administration of
N/OFQ (1 nmol/rat) failed to induce significant changes in the
burying latency, in the number of shocks received and in the
latency to first shock. On the other hand, a decrease in height
[ANOVA: F(3,36) = 10.59, P < 0.01] and duration [F(3,36) = 15.48,
P < 0.01] of burying was assessed in comparison with control
rats, indicating an anxiolytic-like action not significantly
different from that evoked by a single N/OFQ administration
in this test. UFP-101 (10 nmol/rat) did not induce any significant
change per se in respect to controls even though a tendency to
increase test parameters was observed. The pretreatment with
UFP-101 significantly prevented the anxiolytic-like effects of
1 nmol/rat N/OFQ on the height of buried bedding and the total
duration of burying behavior (Table 4).
Finally, the behavioral results obtained form the control
group pretreated with saline 2 h before the subsequent
treatment (experiment 2) were not statistically different from
those induced by the singly saline-treated rats (experiment 1)
in either test (data not shown).ses of nociceptin/orphanin FQ (N/OFQ, 0.3–1.5 nmol/rat) in
g Received electric
shock counts
Height of buried
bedding (cm)
Duration of
burying (s)
3.4  0.51 5.2  0.48 109.3  10.7
4.5  0.56 4.9  0.52 95.9  15.9
5.5  0.94 4.5  0.62 71.6  9.3
3.7  0.87 1.9  0.40* 43.6  8.4*
4.4  0.63 1.0  0.51* 34.7  6.1*
5.3  0.77 0.6  0.45* 27.9  7.3*
ying test. Values are expressed as mean  S.E.M. for 10 rats for each
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Table 3 – Effect of the double administration with nociceptin/orphanin (N/OFQ, 1 nmol/rat, i.c.v.) in the elevated plus maze
test in the rat; influence of the pretreatment with the NOP receptor antagonist, UFP-101 (10 nmol/rat, i.c.v.), thereon
Treatment Time spent
in the
open arms (s)
Time spent
in the
closed
arms (s)
Time spent
in the
central
platform (s)
Open
arm
entry
counts
Closed
arms
entry
counts
Motor
activity in
the open
arms (s)
Motor
activity in
the closed
arms (s)
Saline + saline 77.7  8.9 182.5  16.4 39.8  6.4 3.48  0.59 5.94  0.88 20.31  3.14 36.99  4.18
Saline + N/OFQ 1.0 nmol 136.2  13.7* 115.2  9.8* 48.6  5.7 9.97  1.73* 5.32  0.62 58.76  5.99* 29.35  4.01
UFP-101 10 nmol + saline 83.4  9.6 174.3  14.6 42.3  6.1 2.74  0.61 6.09  0.79 27.52  2.41 31.10  2.99
UFP-101 10 nmol + N/OFQ
1.0 nmol
71.3  7.8 178.0  15.3 50.7  8.1 3.33  0.44 4.94  1.03 21.98  1.84 27.72  4.18
UFP-101 or saline were injected 5 min after N/OFQ or saline and the rats were tested 5 min thereafter in the elevated plus maze. N/OFQ
(1 nmol/rat, i.c.v.) was administered twice, the actual treatment following a pretreatment (same dose) performed 2 h before the beginning of
the experiment. Values are expressed as mean  S.E.M. for 10 rats for each group.
* P < 0.05 vs. saline (two-way ANOVA followed by Bonferroni test).
Table 4 – Effect of the double administration with nociceptin/orphanin (N/OFQ, 1 nmol/rat, i.c.v.) in the conditioned
defensive burying test in the rat; influence of the pretreatment with the NOP receptor antagonist, UFP-101 (10 nmol/rat,
i.c.v.), thereon
Treatment Latency to first
shock (s)
Latency to
bury following
the shock (s)
Received electric
shock counts
Height of buried
bedding (cm)
Duration of
burying (s)
Saline + saline 35.7  3.9 162.1  18.9 3.7  0.72 5.6  0.65 98.7  9.8
Saline + N/OFQ 1.0 nmol 32.5  6.0 138.5  16.8 5.3  0.66 1.4  0.41* 28.9  7.6*
UFP-101 10 nmol + saline 45.2  5.4 227.6  21.0 3.5  0.91 7.9  1.30 126.9  13.3
UFP-101 10 nmol + N/OFQ 1.0 nmol 38.1  4.4 183.6  20.7 4.7  0.77 4.7  0.68 102.3  11.2
UFP-101 or saline were injected 5 min after N/OFQ or saline and the rats were tested 5 min thereafter in the defensive burying test. N/OFQ
(1 nmol/rat, i.c.v) was administered twice, the actual treatment following a pretreatment (same dose) performed 2 h before the beginning of
the experiment. Values are expressed as mean  S.E.M. for 10 rats for each group.
* P < 0.05 vs. saline (two-way ANOVA followed by Bonferroni test).3.3. Serum corticosterone levels
A single N/OFQ administration led to an increase in serum
corticosteronecontents;however thiseffectdidnotproceed ina
dose-dependentmanner. The lowest effective dose in inducing
a significant CORT increase was 0.5 nmol/rat [ANOVA:
F(7,72) = 25.79, P < 0.01]. Surprisingly, the elevation of CORT
levels were significantly lowered after the double N/OFQ
(1 nmol/rat) administration (if compared with the single one)
to a value non-statistically different from the control (Fig. 1).Fig. 1 – N/OFQ or saline (SAL), in single (0.3–1.5 nmol/rat) or
double administration (1.0 + 1.0 nmol/rat after 2 h) were
i.c.v. administered 5 min before the elevated plus maze
test. Twenty minutes thereafter, animals were sacrificed,
blood collected and serum obtained and stocked at S80 8C
for corticosterone (CORT) determination. Values represent
the meanW S.E.M. for 10 rats for each group. *P < 0.05 vs.
controls and §P < 0.05 vs. single dose 1.0 nmol N/O/FQ
(one-way ANOVA followed by Bonferroni test).4. Discussion
The results of the present study show that in the elevated plus
maze, a single i.c.v. administration of N/OFQ affected the rat
behavior in a similarmanner to that of anxiogenic-like agents.
However, a state of hypomotilitymay have interferedwith the
behavioral responses. Following a N/OFQ pretreatment, no
reduction in locomotor activity was observed and the
behavioral response in the plus maze test was consistent
with an anxiolytic-like effect; indeed, classic anti-anxiety
drugs exert similar behavioral effects in rodents [19,43,21].
In the conditioned defensive burying paradigm, burying
height and durationwere decreased either in rats treated with
a single administration of N/OFQ (from the dose of 0.75 nmol/
rat) or in rats that received a double treatment with 1 nmol/rat
N/OFQ.Anxiolytic drugs (e.g. diazepam) decrease duration andheight of burying thus indicating that these parameters can
reflect anxiety-related behavior [44,48,26,27]. Probably, in this
test locomotor activity may be less important for the outcome
of the assay; thus, a clear-cut anxiolytic-like pattern was
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Therefore, the similarities of effects produced by either type of
N/OFQ treatment in this model further suggest an anxiolytic
potential of this drug.
Pretreatment with the potent and selective NOP receptor
antagonist UFP-101 (10 nmol/rat) significantly prevented the
anxiolytic-like effect of N/OFQ (after double injection) in either
anxiety test, indicating that the anxiolytic properties dis-
played by N/OFQ is mediated by the NOP receptor. Thus, our
results demonstrate that the blockade of N/OFQ-NOP signaling
is able to affect exogenous N/OFQ-mediated anxiety-related
behaviors in rats.
Our findings are in accordance with other reports, in which
anxiolytic-like effects of N/OFQ, or of the NOP receptor agonist
Ro 64-6198, were observed in mice and in rats across several
behavioral paradigms generating different types of anxiety
states [21,22,18]. Our data are also in keeping with the results
observed by Koster et al. [23] showing that pre-proN/OFQ
knockoutmice express high levels of anxiety-related behavior
in neophobic tests. The ‘‘anxiogenic-like’’ effect measured in
the elevated plusmaze after single N/OFQ administrationmay
be explained on the basis of the simultaneous occurrence of a
sharp hypolocomotor effect induced by the peptide, effect that
undergoes rapid development of tolerance after repeated
injections, as indicated by Devine et al. [9].
Fernandez et al. [13] reported that i.c.v. injection of N/OFQ
(0.001–1 nmol/rat) increases anxiety-related behavior in rats,
using three neophobic tests including the elevated plus maze
test; these behavioral findings were associated with increased
circulating concentrations of corticosterone. However, it
should be emphasized that these results were obtained
following acute injection of N/OFQ, that is in conditions in
which also in our experimental schedule the results of the
elevated plus maze were suggestive of an anxiogenic effect.
The present study indicates that the effect of N/OFQ in tests of
anxiety may be markedly influenced by the emotional
consequences of its hypolocomotor effect in stressful condi-
tions; therefore it will be interesting to investigate the effect of
repeated injections of N/OFQalso in the other tests used by the
group of Fernandez et al. [13].
N/OFQ tolerance to hypolocomotion may depend on
desensitization and/or internalization processes of the NOP
receptor after repeated administration of the agonist. Spam-
pinato et al. [46,47] reported that N/OFQ can promote
internalization of the human NOP (hNOP) receptor in the
neuroblastoma cell line SK-N-BE, and that beta-arrestin 2 was
involved in this process. An alternative hypothesis also
proposed, is that exogenous administration of N/OFQ into
the VTA produces an immediate long-lasting desensitization
of the NOP receptor [38].
Additional mechanisms indicating the dopaminergic sys-
tem as a target for N/OFQ in this regard are suggested by the
observations that dopamine neurons, probably mesolimbic,
are involved in N/OFQ-inducedmodulation of locomotion and
its tolerance [36,37]. Finally, biphasic effects, like the inverted
U-shape function for N/OFQ effect on locomotion [45,9,10,36]
are generally suggestive of the presence of multiple sites of
action or ofmultiple receptor subtypes for the drug; in the case
of N/OFQ the existence of different subtypes of NOP receptors
has not been elucidated yet. These evidences stronglysuggests that N/OFQ may act via distinct mechanisms/path-
ways to induce the complex behavioral response to stressful
events and could also explain the maintenance of its effect on
anxiety-related behaviors in the presence of a rapid onset of
tolerance to hypolocomotion after double administration.
Furthermore, in our experimental conditions N/OFQ dose-
dependently increased plasma corticosterone levels following
acuteadministration, inkeepingwithprevious reports showing
that N/OFQ activates the HPA axis in unstressed rats and
increaseshormonal responses in thepresenceofamildstressor
[11,12]. Interestingly, a previous treatment with N/OFQ sharply
reduced the effect of the peptide on corticosterone.
Elevations in the circulating concentrations of CORT were
reported for both anxiolytic and anxiogenic drugs (i.e.
diazepam and FG 7142) following acute administration
[29,42,30,8,2,13], and the correlation between emotional
(anxiolytic versus anxiogenic) and hormonal effects of these
drugs seems to be not clear. Thus, CORT responses and
anxiety behaviors can be dissociated, the role of CORT being of
lesser importance in the induction of anxiety. The anxiolytic
actions of N/OFQ are, therefore, likely to arise from central
actions of N/OFQ after i.c.v. administration rather than from
some indirect response involving circulating CORT.5. Conclusions
The results of the present study serve to indicate that i.c.v. N/
OFQ treatment produces a clear-cut anxiolytic-like effect only
in conditions inwhich the hypolocomotor effect of the peptide
is not observed. The serum CORT levels do not seem to be
correlated with the anxiety status in our conditions. Taken
together, these findings are an important step to facilitate the
elucidation of the role of N/OFQ as a regulator of acute anxiety
responses. Finally, they once more contribute to strengthen
the hypothesis that N/OFQ neurotransmission may partici-
pate in normal processing of emotionally salient and stressful
stimuli and disregulation of the N/OFQ-NOP system may be
involved in psychiatric disorders associated with an altered
activity of the HPA axis and/or pathological anxiety states.
Further studies with metabolically stable agonists for the NOP
receptor will be required to evaluate their potential anxiolytic
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